As of Oct 19
| +0.0084 / +1.21%|
The 3 analysts offering 12-month price forecasts for Catabasis Pharmaceuticals Inc have a median target of 3.00, with a high estimate of 7.00 and a low estimate of 1.50. The median estimate represents a +328.63% increase from the last price of 0.70.
The current consensus among 3 polled investment analysts is to Buy stock in Catabasis Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.